Purinoceptor: a novel target for hypertension

Purinergic Signal. 2023 Mar;19(1):185-197. doi: 10.1007/s11302-022-09852-8. Epub 2022 Feb 18.

Abstract

Hypertension is the leading cause of morbidity and mortality globally among all cardiovascular diseases. Purinergic signalling plays a crucial role in hypertension through the sympathetic nerve system, neurons in the brain stem, carotid body, endothelium, immune system, renin-angiotensin system, sodium excretion, epithelial sodium channel activity (ENaC), and renal autoregulation. Under hypertension, adenosine triphosphate (ATP) is released as a cotransmitter from the sympathetic nerve. It mediates vascular tone mainly through P2X1R activation on smooth muscle cells and activation of P2X4R and P2YR on endothelial cells and also via interaction with other purinoceptors, showing dual effects. P2Y1R is linked to neurogenic hypertension. P2X7R and P2Y11R are potential targets for immune-related hypertension. P2X3R located on the carotid body is the most promising novel therapeutic target for hypertension. A1R, A2AR, A2BR, and P2X7R are all related to renal autoregulation, which contribute to both renal damage and hypertension. The main focus is on the evidence addressing the involvement of purinoceptors in hypertension and therapeutic interventions.

Keywords: Endothelium; Hypertension; Neurotransmitter; Purinergic signalling; Purinoceptor.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate / physiology
  • Endothelial Cells*
  • Humans
  • Hypertension*
  • Receptors, Purinergic / physiology
  • Signal Transduction
  • Synaptic Transmission

Substances

  • Receptors, Purinergic
  • Adenosine Triphosphate